Assessment of flow-mediated dilation in humans: a methodological and physiological guideline

Dick H. J. Thijssen,1,2 Mark A. Black,1,3 Kyra E. Pyke,4 Jaime Padilla,5 Greg Atkinson,1 Ryan A. Harris,6 Beth Parker,7 Michael E. Widlansky,8 Michael E. Tschakovsky,9 and Daniel J. Green1,10

1Research Institute for Sport and Exercise Science, Liverpool John Moores University, Liverpool; 2Department of Physiology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 3Vascular Laboratory, Russells Hall Hospital, Dudley Group Of Hospitals, NHS Foundation Trust, Dudley, United Kingdom; 4Cardiovascular Stress Response Laboratory and 5Human Vascular Control Laboratory, School of Kinesiology and Health Studies and Department of Physiology, Queen’s University, Kingston, Ontario, Canada; 6Department of Biomedical Sciences, University of Missouri, Columbia, Missouri; 7Department of Pediatrics, Georgia Prevention Institute, Medical College of Georgia, Augusta, Georgia; 8Department of Preventive Cardiology, Hartford Hospital, Hartford, Connecticut; 9Departments of Medicine and Pharmacology and the Cardiovascular Research Center, Medical College of Wisconsin, Milwaukee, Wisconsin; 10School of Sport Science, Exercise and Health, The University of Western Australia, Crawley, Western Australia, Australia

Submitted 14 May 2010; accepted in final form 8 October 2010

IN GENERAL TERMS, flow-mediated dilatation (FMD) can describe any vasodilatation of an artery following an increase in luminal blood flow and internal-wall shear stress (Fig. 1). However, the term has conventionally come to describe subtle variations of the technique introduced by Celermajer, Deanfield, and colleagues in the Lancet in 1992 (14). This landmark paper introduced an approach involving assessment of peripheral conduit artery diameter following a period of distal limb ischemia. The Celermajer/Deanfield approach was based on several key studies and observations. Nobel prize-winning experiments by Furchgott (33) established that the endothelium produces a labile vasodilator substance, whereas animal studies established that FMD in arteries was dependent on the presence of an intact endothelial lining (93, 108) and that shear stress-sensitive ion channels existed in endothelial cells (16, 63, 83). Rubanyi, Vanhoutte, and colleagues (102) indicated that, in response to flow, the endothelium released a substance that possessed the characteristics of Furchgott’s endothelium-derived relaxing factor, later identified as nitric oxide (NO) (78), and in situ studies using NO antagonists decreased FMD (17, 48). Subsequent animal studies consolidated the link between increases in flow, wall shear stress, endothelial NO synthase expression, and NO bioactivity (6, 123). The accumulated

Address for reprint requests and other correspondence: Dr. D. Thijssen, Research Inst. for Sport and Exercise Science, Henry Cotton Campus, Liverpool John Moores Univ., 15-21 Webster St., Liverpool, L3 2ET, UK (e-mail: d.thijssen@ljmu.ac.uk).
evidence strongly suggested that flow-associated shear was the physiological stimulus to endothelium-mediated vasodilation in vivo. In humans, Vallance, Collier, and Moncada (124) established that NO production occurs basally and in response to pharmacological stimulation, whereas increases in flow-associated shear subsequent to differing periods of arterial occlusion induced vasodilation of large conduit arteries (3, 80, 104, 107). Although Celermajer, Deanfield, et al. (14) provided no direct evidence that their FMD technique induced dilation that could be blocked by NO antagonists, they reasonably assumed from the evidence available at the time that the dilator response was likely to be endothelium dependent and NO mediated. Studies performed after the Celermajer and Deanfield paper largely confirmed the assumption that their FMD technique was NO dependent. Joannides et al. (52) published evidence that radial artery dilation (FMD\textsubscript{3.6%}) following 3 min of ischemia was converted to constriction (−2.8%) in the presence of NO blockade with N-monomethyl-L-arginine (52). Mullen et al. (79) found that NO blockade decreased the radial artery FMD response to 5-min ischemia from −5.3% to 0.7%, with no difference in the hyperemic blood-flow stimulus, making it unlikely that stimulus magnitude reductions explained the FMD response abolition. However, 15 min of ischemia induced a radial FMD response, which was not affected by NO blockade (79). This supported the notion that the duration of ischemia was an important determinant of the mechanisms responsible for the subsequent vasodilator responses (79). More recently, the superficial femoral artery FMD, induced by a 5-min cuff occlusion period, was found to be largely NO dependent (61). Therefore, most (52, 61, 68, 79), but not all (96), studies suggest that FMD can be substantially attenuated by NO blockade. Taken together, these physiological studies generally reinforced the validity of the approach introduced by Celermajer and Deanfield as an endothelium-dependent and NO-specific index of endothelial function (14). FMD has become popular in clinically orientated studies, in part, because it strongly predicts cardiovascular events in patients with established cardiovascular disease (Table 1). These studies generally indicate that FMD provides independent prognostic information, which may exceed the predictive value of traditional risk factors (Table 1). Studies that have examined the prognostic role of FMD in asymptomatic subjects have suggested a more modest association (31, 32, 132), and it has been suggested that FMD may become less predictive in older individuals in whom arterial distensibility may be limited (129, 133) (Figs. 1–4). In summary, FMD appears to be predictive of cardiovascular events in asymptomatic subjects and those with established cardiovascular diseases. FMD appears at least as predictive as traditional risk factors (Table 1), a conclusion supported by a recent meta-analysis (49). More-
over, a change in FMD may also provide important prognostic information in humans (Table 1).

The FMD technique has increasingly been applied in physiological studies to examine the mechanisms that underlie the acute or chronic impact of stimuli that alter vascular function and risk (e.g., exercise training, smoking, hypercholesterolemia, hypertension) (20, 26, 34, 41, 54, 81, 101, 134) or to study hemodynamic effects on the vasculature in vivo (85, 87, 100, 117, 126). Given the widespread use of FMD, methodological approach can critically impact the nature and magnitude of the FMD response (10, 25, 79). Whereas previous studies have identified important physiological and technical issues that can impact the validity, reproducibility, and interpretation of FMD studies (5, 8, 10, 40, 45, 55, 70, 85, 86, 90, 97, 99, 100, 113, 117, 126). Given the widespread use of FMD, these issues merit detailed discussion. This review results from discussion between several distinct research groups who have independently worked to provide an evidence base and physiological background for the improvement of the practical guidance and technical approaches to FMD measurement and analysis.

Technical Issues Pertaining to Duplex Ultrasound Assessment of FMD

**Diameter and velocity assessment.** High-resolution B-mode ultrasound has become the research tool of choice for measuring conduit artery diameter for FMD assessment. The main advantages of B-mode ultrasound are that it is relatively cost effective, noninvasive, portable, and reproducible when following appropriate training and experience (22–24, 130). The main challenge with B-mode imaging is to identify clear vascular boundaries. Imaging of a blood vessel in the longitudinal plane allows visualization of the double lines of Pignoli (92), distinguishable demarcated boundaries that allow for precise diameter measurement (≤0.05 mm) (130) by automated edge-detection software.

Because of the recent acknowledgment of the importance of quantifying shear stress during the FMD responses (86, 99, 100), duplex ultrasound for simultaneous acquisition of B-mode diameter and pulsed-wave Doppler velocity signals is recommended where available. An important limitation of duplex ultrasound is that the same transducer is employed to detect signals for both the Doppler frequency shift as well as the arterial diameter, which have competing requirements for optimal data acquisition. B-mode echoes are of greater intensity with perpendicular incidence of the ultrasound beam to the vessel orientation (90 degrees), whereas optimal pulsed-wave Doppler signals require parallel incidence with the direction of

<table>
<thead>
<tr>
<th>Authors</th>
<th>Journal</th>
<th>Year</th>
<th>N</th>
<th>Group</th>
<th>FMD As A Predictor</th>
<th>Subjects with CVD or CVD Risk</th>
<th>Healthy Subjects</th>
<th>Change in FMD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shechter et al.</td>
<td>IJC</td>
<td>2009</td>
<td>435</td>
<td>men and women</td>
<td>single FMD: NP (future events)</td>
<td>P (future CVD)</td>
<td>FMD increase after 26 mo fewer events</td>
<td></td>
</tr>
<tr>
<td>Kitta et al.</td>
<td>JACC</td>
<td>2009</td>
<td>251</td>
<td>CAD</td>
<td>single FMD: NP (future events)</td>
<td>IP (future CVD)</td>
<td>FMD increase after 10 mo fewer events</td>
<td></td>
</tr>
<tr>
<td>Yeooh et al.</td>
<td>Circ</td>
<td>2009</td>
<td>3026</td>
<td>men and women</td>
<td>IP (future CVD)</td>
<td>P (future CVD)</td>
<td>FMD increase after 6 mo fewer events</td>
<td></td>
</tr>
<tr>
<td>Rossi et al.</td>
<td>JACC</td>
<td>2008</td>
<td>2264</td>
<td>women</td>
<td>IP (future CVD)</td>
<td>IP (future CVD)</td>
<td>FMD increase after 6 mo fewer events</td>
<td></td>
</tr>
<tr>
<td>Yeooh et al.</td>
<td>Circ</td>
<td>2007</td>
<td>2791</td>
<td>men and women</td>
<td>IP (future CVD)</td>
<td>P (future CVD)</td>
<td>FMD increase after 6 mo fewer events</td>
<td></td>
</tr>
<tr>
<td>Shimbo et al.</td>
<td>Atheroscl</td>
<td>2007</td>
<td>842</td>
<td>men and women</td>
<td>IP (future CVD)</td>
<td>P (future CVD in lowest tertiles)</td>
<td>FMD increase after 6 mo fewer events</td>
<td></td>
</tr>
<tr>
<td>Suessenbacher et al.</td>
<td>Vasc Med</td>
<td>2006</td>
<td>68</td>
<td>CAD</td>
<td>single FMD: NP (future events)</td>
<td>P (future CVD)</td>
<td>FMD increase after 6 mo fewer events</td>
<td></td>
</tr>
<tr>
<td>Karatzis et al.</td>
<td>AJC</td>
<td>2006</td>
<td>98</td>
<td>ACS</td>
<td>P (future events)</td>
<td>IP (stent restenosis)</td>
<td>Endothelial function increase after 8 wk</td>
<td></td>
</tr>
<tr>
<td>Patti et al.</td>
<td>Circ</td>
<td>2005</td>
<td>136</td>
<td>CAD</td>
<td>IP (deterioration and death)</td>
<td>IP (future events)</td>
<td>Fewer ACS</td>
<td></td>
</tr>
<tr>
<td>Meyer et al.</td>
<td>JACC</td>
<td>2005</td>
<td>75</td>
<td>CHF</td>
<td>IP (future events)</td>
<td>IP (survival)</td>
<td>Fewer ACS</td>
<td></td>
</tr>
<tr>
<td>Frick et al.</td>
<td>JACC</td>
<td>2005</td>
<td>398</td>
<td>Chest pain</td>
<td>IP (future events)</td>
<td>IP (survival)</td>
<td>Fewer ACS</td>
<td></td>
</tr>
<tr>
<td>Fischelser et al.</td>
<td>EHJ</td>
<td>2005</td>
<td>67</td>
<td>CHF</td>
<td>IP (future events)</td>
<td>IP (survival)</td>
<td>Fewer ACS</td>
<td></td>
</tr>
<tr>
<td>Fathi et al.</td>
<td>JACC</td>
<td>2004</td>
<td>444</td>
<td>CAD and healthy</td>
<td>IP (in higher risk patients)</td>
<td>NP (in no/low risk subjects)</td>
<td>FMD decrease across time – fewer events</td>
<td></td>
</tr>
<tr>
<td>Gocke et al.</td>
<td>JACC</td>
<td>2003</td>
<td>199</td>
<td>PVD</td>
<td>IP (future events)</td>
<td>IP (future events)</td>
<td>FMD increase after drug treatment – fewer events</td>
<td></td>
</tr>
<tr>
<td>Brevetti et al.</td>
<td>Cir</td>
<td>2003</td>
<td>131</td>
<td>PVD</td>
<td>IP (Low FMD: IP)</td>
<td>IP (future events)</td>
<td>FMD increase after drug treatment – fewer events</td>
<td></td>
</tr>
<tr>
<td>Chan et al.</td>
<td>JACC</td>
<td>2003</td>
<td>106</td>
<td>CAD</td>
<td>IP (FMD/GTN)</td>
<td>IP (future events)</td>
<td>FMD increase after drug treatment – fewer events</td>
<td></td>
</tr>
<tr>
<td>Modena et al.</td>
<td>JACC</td>
<td>2002</td>
<td>400</td>
<td>Hypertension</td>
<td>P (future events)</td>
<td>IP (future events)</td>
<td>FMD increase after drug treatment – fewer events</td>
<td></td>
</tr>
<tr>
<td>Neunetluf et al.</td>
<td>AJC</td>
<td>2000</td>
<td>73</td>
<td>Chest pain</td>
<td>IP (future events)</td>
<td>IP (future events)</td>
<td>FMD increase after drug treatment – fewer events</td>
<td></td>
</tr>
</tbody>
</table>

NP, no predictor; P, predictor; IP, independent predictor; CAD, coronary artery disease, ACS, acute coronary syndrome; CHF, chronic heart failure; PVD, peripheral vascular disease; FMD, flow-mediated dilation; GTN, glyceryl trinitrate; IJC, International Journal of Cardiology; JACC, Journal of the American College of Cardiology; Circ, Circulation; Atheroscl, Atherosclerosis; Vasc Med, Vascular Medicine; AJC, The American Journal of Cardiology; EHJ, European Heart Journal.
blood flow (0 degrees) (62, 82, 118). Consequently, a compromise must be reached to uphold fundamental principles and assumptions for both modalities as well as to minimize the loss of signal quality (82).

Modern duplex ultrasound systems incorporate a narrow Doppler beam aperture that can be steered 20–30° of center of the B-mode imaging beam. This ensures that measurable Doppler shifts are achievable at an approximate angle of 60° between the Doppler beam and the vessel orientation, while maintaining optimal B-mode imaging. For clinical ultrasound, approximation of the Doppler beam-vessel angle ≤60° in relation to the direction of blood flow allows estimation of blood-flow velocity within reasonable levels of measurement error (94) and with adequate quality (46, 62). Because the error associated with incorrect estimation of insonation angle increases exponentially with angles >60° (62, 82, 118), we recommend an insonation angle of ≤60° when velocity assessment is used for shear rate calculation. However, insonation angles above 60° may be validly used under circumstances where extensive flow calibrations have been undertaken (98). In all circumstances, the angle used should be reported in the methods section.

Analysis of velocity signal. Blood-flow velocity can be calculated using the peak (peak Doppler shifts) or mean velocity (intensity weighted mean of all Doppler shifts). The peak-velocity approach measures the fastest moving blood cells, located in the center of the vessel. It is assumed that half the peak velocity is representative of the mean velocity (67). The intensity-weighted mean-velocity approach involves estimating mean velocity from all of the Doppler shifts measured across the cross section of the vessel, from the slower outer lamina to the faster central layers of flow. This latter approach can be limited by incomplete sampling of Doppler shifts across the full width of the artery by the current linear array transducers (118). Because of the narrow Doppler beams, the slower moving peripheral lamellae from the lateral aspects of the artery are not taken into account, even if the Doppler sample gate is widely spaced to encompass the near and far walls of the artery (118). This can overestimate velocity by up to 33% (29).

Both methods of velocity assessment have their merits and disadvantages and do not appear to be interchangeable (30). This should be appreciated when comparing absolute blood flow/velocity values between studies that have adopted different approaches. Moreover, it is advisable to choose a single method within a study and also preferably between studies from the same laboratory. Claims of assessment of absolute blood flow should only be made where ultrasound machines and analysis methods have been validated against phantom artery preparations or string phantoms (130).

From velocity and diameter data, shear rate can be calculated. In most studies shear rate is calculated rather than shear stress, as it is generally assumed that blood viscosity does not differ substantially between individuals and/or groups or after interventions (11, 35, 86). In a recent study, it was demonstrated that the addition of viscosity measurements does not have a significant impact on shear stress calculations and does not alter the interpretation of the FMD results (86). Because different approaches have been adopted to calculate shear rate (90), caution is warranted when comparing shear rate data between studies. We recommended using identical settings within and between studies from one laboratory (23). In addition, calculations should all be clearly described in the methods sections given the fact that different methods can impact on absolute values as explained above.

**Methodological Considerations Pertaining to FMD Assessment**

**Subject preparation.** FMD can be influenced by dietary intake (7), recent aerobic or resistance exercise (20, 41, 75, 120), caffeine and alcohol ingestion (44, 88), and supplement/medication use (39, 72, 111). We therefore recommend assessing FMD when subjects are fasted and have avoided exercise, caffeine, alcohol, drugs, stimulants, and medications for a consistent period of time (at least 6 h) to minimize the effect of these confounding factors (Table 2). In the case of clinical populations in whom medication use cannot be avoided, tests should be conducted after a standardized period of time following medication and a careful history of medication use and

| Table 2. Recommendations for FMD assessment to examine a largely nitric oxide-mediated, endothelium-dependent vasodilation of a conduit artery in humans |
| Methodological and Technical Guidelines |
| **Subject Preparation** |
| - Rest in a quiet, preferably darkened room for a period of ≥20 min before assessment. |
| - Supine posture (i.e., the imaged artery should not be substantially above or below heart level). |
| - Tests should be standardized and, for multiple tests, conducted at a similar time of day. |
| - Cuff must be placed distal to the imaged artery and inflated for 5 min. |
| - Subjects must be fasted for ≥6 h. |
| - Subjects must avoid exercise or food/drinks that contain caffeine or alcohol for ≥8 h. |
| - Careful history should be taken regarding the use/timing of drugs because some drugs have an effect. |
| - Premenopausal women should be assessed on days 1–7 of the menstrual cycle. |
| **Protocol** |
| - Baseline diameter must be examined before cuff inflation for a period of at least 1 min. |
| - Present absolute baseline diameter should be in results section. |
| - Measurement of postdeflation diameter should start before cuff release. |
| - Measurements should be performed for ≥3 min in upper limb arteries and ≥5 min in lower limb arteries. |
| **Technique** |
| - Continuous measurement of velocity and diameter using duplex ultrasound should be performed. |
| - Blood velocity should be assessed using an insonation angle of ≤60°. |
| - Use the same angle within a study and study group (and report angle). |
| - B-mode images with a probe of ≥7.5 MHz should be used (and report probe details). |
| **Analysis** |
| - Continuous edge detection and wall tracking should be used to capture true peak diameter and for calculation of shear rate. |
| - Peak velocity outer envelope assessment is recommended for analysis of the Doppler signal. |
| - Automated mathematical algorithms should be used to calculate the peak diameter. |
| - Present the FMD response in absolute (in mm) and relative (in %) change. |
| - The relevant shear-rate stimulus (area-under-the-curve until peak diameter) must be presented. |
| - The use of ratio normalization (e.g., FMD/shear) is currently unresolved, and at this time no recommendation to use such normalization can be provided. |
Analysis: edge detection and wall tracking. Initial studies using the FMD technique relied on manual assessment of vessel diameters using visual inspection of single frames and placement of ultrasonic calipers at discrete points along the long axis of the B-mode image (13, 14). This method of manual assessment is highly operator dependent and subject to significant observer error (38, 74, 95, 130). Computer-assisted analysis, utilizing edge-detection and wall-tracking software, permits multiple measurements along the vessel wall. Studies comparing the validity and reproducibility of computerized edge-detection and wall-tracking systems demonstrate significantly lower intraobserver variation for the automated systems than for the manual technique (95, 109, 130). Therefore, validated, accurate, and reproducible edge-detection and wall-tracking systems should be used to improve the validity of the FMD measurements.

Protocol: assessment of peak diameter. In the first studies using FMD, peak artery diameter was assessed on a single frame at 60 s postdeflation (Fig. 2) (13, 14). The reason for defining 60 s as the appropriate time to take a peak diameter measure dates back to the original work of Celermajer, Deanfield et al. (14). Although this approach is still used (43, 57, 128), recent papers have questioned the validity of this technique to detect the “true” peak diameter (10, 114).

Peak diameter in the BA. It was recently demonstrated that calculating FMD on the basis of the 60-s value can lead to a 25–40% underestimation of the true FMD in humans (10) (Fig. 3). Also, a predetermined time window (e.g., 50–70 s) can result in an underestimate of the true maximal FMD (10). This may lead to a systemic reduction in the effect size of interventions and result in type II statistical errors (71). Because the time to peak diameter differs between (10, 71, 85) and within (50) groups, measurement of time to peak diameter as a potential simple marker of risk has attracted interest. However, recent data have been interpreted as indicating that the time to peak diameter is at least partially NO independent and that the time to peak diameter does not appear to be a useful adjunctive measure of endothelial health (71). These studies, nonetheless, endorse continuous measurement of arterial diameter responses during FMD. On the basis of available data, an assessment period of at least 180 s for the brachial artery seems warranted when assessing the FMD, with most peak measurements occurring in the first 120 s after cuff release (10). Further work remains to determine the determinants and utility of time to peak diameter measurement.

Identification of peak diameter: timing of diameter measurements and size of time bins. The 2002 guidelines recommended measurement of the brachial diameter at end diastole to limit the influence of potential differences in vascular
compliance on diameter measurements (18). However, interpretation of recent data indicates that FMD (and nitroglycerin-mediated dilation) measurements using an average of the vessel diameter over the entire cardiac cycle yield equivalent results over a wide range of vascular compliance (55, 85).

Another aspect of FMD analysis is the identification of the peak dilation. For current, automated diameter analysis systems, various time bins have been used to average the peak diameter and subsequently calculate FMD, varying from 3 s up to 10 s (10, 28, 39, 41, 85, 86). Shorter time bins (e.g., 1 s) will likely result in greater peak diameter and FMD, whereas longer bins (e.g., 10 s) will result in a lower FMD. A recent study reported that the FMD is significantly lower when using a 10-s time bin compared with 3- or 5-s time bins (38). In light of these data, we recommend that laboratories apply a consistent time-bin methodology and report the method used.

**OTHER CONDUIT ARTERIES.** An increasing number of studies are examining endothelial function in conduit arteries such as the posterior tibial (56, 110), popliteal (9, 87, 89, 119), superficial femoral (13, 21, 116, 131), deep femoral (131), and common femoral (114) arteries. These studies have largely assumed that, when adopting the typical FMD methodological approach, the NO-dependent nature is comparable to that observed in the radial artery (61, 68, 79). However, confirmatory evidence to this effect exists only for the superficial femoral artery (61). Because endothelial NO synthase content is heterogeneous throughout the arterial tree (64), the relative contribution of NO to FMD may differ between conduit vessels. In addition, arteries in the legs demonstrate a significantly later peak than those in the arms (114). This means that the 3-min postdeflation time window for the brachial artery is unlikely to capture the peak diameter in arteries of different size, location, and structure. This should be taken into consideration when examining the dilator response in arteries of different size. Therefore, we recommend a 5-min time window to capture the peak diameter in arteries other than the brachial artery. Further work is necessary to establish the NO dependence of FMD responses in conduit vessels other than the radial and superficial femoral arteries.

**Protocol: assessment of baseline diameter.** The FMD response is characteristically presented as a change from baseline diameter. In the classic approach (11), baseline diameter has been defined as the diameter preceding cuff inflation, and this remains the most frequently adopted method in the literature (16, 30, 69, 93, 98, 109). This approach has been used in studies of prognosis (n = ~10,000, Table 1), such that data indicating that FMD is clinically relevant fundamentally assume that FMD is calculated using a precuff inflation baseline.

Some recent physiological studies have assessed baseline diameter at the end of the cuff inflation (20, 72, 73, 79, 81). The rationale for this is that restoration of the occlusion-induced change in diameter represents an integrative part of the FMD response itself. Some studies suggest that radial artery vasoconstriction occurs during distal cuff inflation (36, 125), whereas recent studies examining the brachial diameter during occlusion demonstrate conflicting results (89, 99, 117, 125). One recent study directly compared the impact of using precuff inflation vs. end-of-cuff inflation diameter on brachial artery FMD (95). The brachial artery diameter during cuff inflation was significantly larger than that assessed preinflation, consequently leading to a significantly different FMD. More importantly, this effect of cuff inflation on the baseline diameter differed across different age groups. The typical age-related reduction in FMD was not found when the baseline diameter preceding cuff deflation was used (95). Given that the impact of occlusion on arterial diameter differs among populations (95), we recommend using the preocclusion diameter as the baseline value.

**Shear stimulus and the FMD response.** Several studies have demonstrated, using various manipulations of the shear-stress stimulus within subjects, that exposure to shear stress leads to diameter increases in a dose-dependent fashion (8, 65, 85, 99). The close relationship between a change in shear stimulus and a change in diameter indicates that the shear stimulus is the eliciting stimulus for artery dilation during the FMD response (76). When shear stress increases, this signal is transduced by the endothelial cells and stimulates the release of vasoactive substances, which then act on the vascular smooth muscle (4, 59). The magnitude of dilation is therefore determined by 1) the characteristics of the shear-stress stimulus (e.g., amount, pattern), 2) the transduction of the vasodilator response to the smooth muscles, 3) the response of the smooth muscle to a given vasodilator signal through changes in calcium concentrations, and 4) the resulting diameter change, which may be affected by structural characteristics of the vessel wall (58, 66).

**WHAT PORTION OF THE REACTIVE HYPEREMIA PROFILE IS RELEVANT TO FMD-RESPONSE DEVELOPMENT.** The postdeflation shear profile is transient in nature, and there is a significant delay between the peak shear rate and the peak diameter (18) (Fig. 2). This raises questions about which part of the reactive hyperemia shear profile represents the relevant stimulus for dilation. Both postdeflation peak shear rate and the entire stimulus-untillpeak diameter have been hypothesized to contribute to the FMD-response magnitude (99, 105). Pyke and Tschakovsky (99) were the first to truly examine this matter and performed a series of experiments in which they independently manipulated the peak or the total shear-rate stimulus. These experiments demonstrated that the total, rather than peak, shear rate determines the magnitude of the FMD response (99). This finding was recently confirmed by others (86).

It is also important to mention that it is not possible, using some machines, to simultaneously have active B-mode and pulsed-wave velocity windows in duplex mode. This, along with the fact that simultaneous “live” velocity and diameter measures can degrade B-mode image resolution in older machines, has led to the practice of recording velocity for an initial period (e.g., 30 s) followed by a switch to diameter measurement to capture the peak diameter. In this case, it is possible to miss the true peak diameter, and shear rate can only be calculated for the period of time during which velocity measures are recorded. The validity of this approach to shear calculation rests on whether there is a similar correlation between FMD and the shear-stress stimulus calculated up to, e.g., 30 s, compared with the individualized time-to-peak diameter. In this context, one recent study suggested that a good correlation existed between shear rate calculated to 30 s, 60 s, and to the individual peak diameter (113). Therefore, measuring the first 30 s of the shear-stress stimulus may
represent a valid alternative under some circumstances, but the optimal approach must be to continuously collect high-resolution Doppler and B-mode images to the time of peak diameter for the calculation of shear.

**RELATIONSHIP BETWEEN SHEAR STRESS AND FMD: BETWEEN-SUBJECT COMPARISONS.** In contrast to the within-subject studies (8, 65, 86, 99), the relationship between shear and FMD may be weak when between-subject comparisons are undertaken (Figs. 4 and 5). For example, a recent study found a correlation between total shear rate area-under-the-curve and FMD in young adults ($r^2 = \sim0.15$), whereas no correlation was evident in either children or older adults (113). This does not undermine the role of shear stress as the stimulus for FMD but primarily illustrates the importance of biological variability in the FMD response to shear stress attributable to variability in the above steps 2-4 (Fig. 1). It can be appreciated that different individuals may have the same FMD even though they have experienced substantially different shear-stress stimuli (or vice versa, Fig. 4). A conclusion that similar FMD in this situation reflects similar endothelial function could be potentially misleading, as would a conclusion that different FMD is attributable to different shear stress. Given the importance of shear rate, we recommend measuring and presenting the shear stimulus until peak diameter (85, 86, 99).

**FMD ANALYSIS: STIMULUS NORMALIZATION.** The FMD test elicits a reactive hyperemia stimulus, which is variable between subjects (51, 86, 97) and determined by several factors (15, 77, 106, 122). Consequently, when distinct FMD responses are observed between groups or individuals, it may be unclear whether this is attributable to differences in biological variability in endothelial function per se or differences in the magnitude of reactive hyperemia (Fig. 5). This raises the issue of how to account for the magnitude of the stimulus when interpreting FMD results.

On the basis of the relationship between FMD and eliciting shear-rate stimuli within young healthy subjects described above (8, 65, 86, 99), researchers began normalizing the FMD responses by dividing the FMD by shear rate (21, 86, 89). However, important questions have since arisen regarding the validity of this approach (5, 40). When adopting this type of normalization, there must be at least a moderate correlation between shear and FMD in each particular research setting (2, 5). This correlation should also be relatively stable in all the groups or experimental conditions that are examined in any study (5, 40). If the relationship between shear and FMD is weak and/or inconsistent between study groups, then shear normalization may be misleading and decrease statistical power (5). Whereas a strong relation between the “dose” of shear rate and the FMD is observed within young subjects (97, 99, 100), a relatively weak relation has been found between young healthy subjects (114), with no relation reported in other groups (113) (Figs. 4 and 5).

Even if there is a moderate to strong relationship between shear and FMD, as suggested by within-subject comparisons, the accuracy of normalization depends on the characteristics of this relationship in each research setting (2, 5). Relevant assumptions for the use of ratios indicate that normalization is valid if 1) the relationship between both parameters is linear, 2) the intercept for the regression slope of this relationship is zero, 3) data (including residuals) are normally distributed, 4) variances are similar between groups, and 5) the ratio does not lead to spurious correlations with other variables (2) (Fig. 5). For any normalization approach to be appropriate, the covariate (i.e., shear) should be at least moderately correlated to the outcome (i.e., FMD) (5). Thin solid lines represent hypothetical within-subject shear-FMD relationships, where the dilatation is presented to 5 incremental shear-stress stimuli. The good within-subject shear-FMD relationship suggests that normalization is appropriate when using a within-subject comparison in this data set. The thick solid line represents the between-subject correlation fitted across the mean values for the 5 subjects. A between-subject correlation is present in this data set, which is a necessary assumption for normalization in cross-sectional studies. Interindividual variation is expected in 1) the response of shear to the hyperemic stress, 2) the slope of within-subject relationship, and 3) the intercept of within-subject relationship.
5). A recent study found that all assumptions for reliable use of FMD/shear ratios were violated in the comparison of FMD between samples of boys, young men, and older men (5). Logarithmic transformation of shear rate and FMD improved adherence to assumptions in this particular study (5), but it was recommended that this and other methods of normalization, such as analysis of covariance (5, 40) or allometric scaling (5), should be further investigated before widespread use. In essence, the accuracy of FMD normalization via simple division by shear rate depends on the shear-FMD relationship being at least moderately strong and consistent between groups or conditions. If these conditions are not met, this process will be inconsistently applied across these groups and conditions (2), leading to inaccurate conclusions (5).

SUMMARY: SHEAR STIMULUS AND THE FMD RESPONSE. Taken together, there is a physiological and mechanistic basis for considering the impact of shear rate when interpreting FMD responses because increased shear is the stimulus for FMD (76). However, there are various factors that can influence the transduction of shear stress into conduit artery dilation. These factors may be both methodological [e.g., cuff position, duration of shear, and duration of ischemia (7, 8, 25, 79, 86)] and physiological [e.g., arterial stiffness, flow pattern, and blood viscosity (12, 73)] and have not been fully described or accounted for. Moreover, there is evidence both for (85) and against (5, 113, 114) using a ratio normalization of the dilatory response to shear rate. In addition, the relationship between shear rate and FMD may not be linear, and the mathematical assumptions necessary to normalize FMD to shear are invalidated in certain study populations (5). On the basis of this current evidence, we endorse measuring shear and acknowledge it as the eliciting stimulus for FMD. Researchers should ideally report the total shear-rate stimulus and, if necessary, investigate the relationship between it and the dilatory response in their publications. However, the use of ratio normalization (FMD/shear) is presently unresolved, and at this time it is not possible to recommend a method for correcting for differences in shear. Further research will be necessary to (1) accurately quantify the shear response to occlusion (to improve and validate estimation of the shear stimulus) and (2) determine how best to account for the shear stimulus in relation to the conduit artery dilation for widespread utility of the FMD procedure.

Recommendations for FMD Assessment and Future Perspectives

The FMD technique will soon enter its third decade as a research tool in humans. There are many attractive reasons to pursue this technique, including the fact that it provides a noninvasive and direct measure of artery function and health in vivo. There is increasing evidence that FMD provides valuable and independent prognostic information in humans. However, different methodological approaches limit its validity, comparability, and its potential use as a clinical and physiological research tool. In addition, improving understanding of the physiological and technical principles underpinning the FMD technique will improve its application and interpretation of (patho)physiological changes that may occur between groups or after interventions. Performing and reporting FMD in a manner consistent with the physiology of the response to shear stress will ultimately improve the accuracy of FMD measurement for prediction of future clinical risk and as a methodological investigative tool. This review has provided an updated physiological rationale for the techniques employed in FMD assessment. In addition, several unresolved issues in the practice of FMD were highlighted, and it is expected that this will stimulate further work aimed at improving what has become an extremely popular research and clinical measurement tool.

GRANTS

D. J. Green received funding from the National Heart Foundation of Australia and the Australian Research Council. D. H. J. Thijssen is supported by the Dutch Heart Foundation (E. Dekker stipend). M. E. Widlansky is supported by K23HL089326, AHA-ASP MGrant-in-Aid 10GRNT3880044, and the Greater Milwaukee Foundation. M. E. Tschakovsky is supported by funding from the Natural Science and Engineering Research Council of Canada. R. A. Harris is supported by a Scientific Development Grant (10SDG3050006) from the American Heart Association. B. Parker is supported by NIH 1R01HL098085-01. J. Padilla is supported by the NIH T32 AR048523. K. E. Pyke is supported by funding from the Natural Science and Engineering Research Council of Canada.

DISCLOSURES

The authors have no conflicts of interest to disclose.

REFERENCES


